NGHIÊN CỨU ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG, VÀ ĐÁNH GIÁ KẾT QUẢ ĐIỀU TRỊ SUY TIM PHÂN SUẤT TỐNG MÁU GIẢM BẰNG THUỐC SACUBITRIL /VALSARTAN

Abstract

Background: Heart failure is one of the cardiovascular diseases with a high burden of disease. Patients are frequently hospitalized for acute heart failure, the re-hospitalization rate is about 30-50%, the cost of care is high for both drug and non-drug treatment, and the mortality rate is high 48-57%. Objectives: To describe clinical and paraclinical characteristics and evaluate the results of treatment of heart failure with reduced ejection fraction with Sacubitril/Valsartan at Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital. Subjects and methods: Randomized study of 98 patients with heart failure with reduced ejection fraction hospitalized and treated at Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital. Results: The mean age of the patients was 67.0 ± 13.7, men accounted for 63.3%. Shortness of breath is the most common symptom (82.7%), other symptoms are also common such as distended neck veins, peripheral edema, rales in the lungs. The mean ejection fraction was 30.76 ± 7.03%. The median of NT-proBNP concentrations was 6745 pg/ml. After a 2-month follow-up period, there was no significant difference in the rate of re-hospitalization for heart failure in the group of patients who used and did not use Sacubitril/Valsartan, the rates are 9.1%, 25.9% respectively (p = 0.524). Conclusions: Shortness of breath is the most common symptom in patients with heart failure with reduced ejection fraction. The rate of re-hospitalization for heart failure after 2 month of treatment was lower in the group of patients who used Sacubitril/Valsartan than in the group who did not use Sacubitril/Valsartan, but this difference was not statistically significant.